menu search

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
– Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the Phase 3 PaTHway Trial – At Week 52, 95% of patients treated with TransCon PTH achieved independence from conventional therapy – TransCon PTH treatment improved mean patient-reported […] The post One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 ap... Read More
Posted: Jun 17 2023, 21:30
Author Name: forextv
Views: 102079

Search within

Pages Search Results: